bioengineer.org
Cure8 news brief
Why This Matters
This report documents one‑year outcomes after fecal microbiota transplantation in four very ill children across several indications, including a child with Crohn’s disease and severe C.
difficile infection — information that may be of interest to families and clinicians exploring microbiome therapies in complex pediatric cases.
Who Should Pay Attention
Pediatric patients and their caregivers, pediatric gastroenterologists, transplant/GvHD specialists, infectious disease clinicians, and researchers studying microbiome therapies and decolonisation of multidrug‑resistant organisms.
Study Snapshot
Story typeResearch news
Evidence typeCase report
Source depthFull source text
What To Know
The two children treated for C. difficile infection (including one with Crohn’s disease) had no recurrence through one year and improved clinically by day 14 in the report.
One child with graft‑versus‑host disease showed clinical control of gastrointestinal symptoms by day 14 but later died from a cerebral fungal infection; the authors could not definitively exclude donor‑derived transmission.
In the child with IPEX syndrome and multidrug‑resistant organism carriage, initial oral capsule FMT did not clear carriage by day 14; after a repeat dose at day 60, cultures were negative at days 90 and 365.
Methods of delivery varied (nasojejunal/nasogastric tube, colonoscopy, oral lyophilised capsules), and the cases had different goals (infection remission, GvHD control, decolonisation).
What this does and does not show: These are individual cases without a control group, small numbers, and mixed indications, so the report documents that FMT was administered and describes outcomes in selected patients but does not establish safety or efficacy for broader pediatric IBD, C. difficile, GvHD, or decolonisation use.
The authors call for larger controlled studies to assess selection and long-term outcomes.
Keep In Mind
Small case series without controls and heterogeneous indications limit generalisability. One death from a fungal infection raised unresolved concerns about possible donor‑derived infection; investigators did not attribute the fatality directly to FMT but could not rule out transmission.
The source is a news summary of a peer‑reviewed case report published in BMC Pediatrics (DOI provided).
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbioengineer.org
Indexed viaGoogle News
Source typeWeb article
PublishedOct 21, 2026, 7:18 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Atopic Dermatitis and Risk of Inflammatory Bowel Disease in Children: A Systematic Review and Meta-Analysis
This review found that children with atopic dermatitis have a modestly higher risk of later developing IBD (both Crohn’s disease and ulcerative colitis). Awareness of this association may help clinicians and families...
Analysis of the Intestinal Microbiota in Crohn’s Disease and Therapeutic Potential of Thymus Essential Oils
Findings highlight cultivable gut microbiota differences in Crohn’s disease versus controls and present preliminary in vitro antimicrobial activity of two thyme essential oils—topics that may interest patients following...
Microbiome Breakthrough: New Crohn's Treatment Unveiled
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...